Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study

Fig. 1

PEM is a humanized monoclonal antibody against PD-1 receptor. The activity of T cells may be restored via the checkpoint blockade using PEM. This binding reactivates the T cell signal induced by the interaction between MHC and TCR by initiating the proliferation of T cells and targeting tumor cells. PEM: pembrolizumab; PD-1: programmed cell death protein-1; MHC: major histocompatibility complex; TCR: T cell receptor

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us